Oral News and Research

RSS

Healthcare policies need to adequately address dental health of entire families

Dr. Steven Adair, Chief Dental Officer for FORBA, one of the nation's largest dental practice management firms focused on high-quality dental care for underserved communities, today raised concerns that a new government report on a lack of dental coverage for adults may also underscore ongoing oral health challenges for children from low-income families.

23 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

High blood sugar in mother during pregnancy leads to reduced insulin sensitivity in children

Children of mothers whose blood glucose (sugar) was high during pregnancy are more likely to have low insulin sensitivity—a risk factor for type 2 diabetes—even after taking into consideration the children's body weight, a new study shows. The results will be presented Tuesday at The Endocrine Society's 92nd Annual Meeting in San Diego.

23 Jun 2010

ATP-driven bioluminescence predicts children at high risk for tooth decay: OHSU study

Researchers at the Oregon Health & Science University School of Dentistry have determined that ATP-driven (adenosine triphosphate-driven) bioluminescence - a way of measuring visible light generated from ATP contained in bacteria - is an innovative tool for rapidly assessing in children at the chair-side the number of oral bacteria and amount of plaque that can ultimately lead to tooth decay.

23 Jun 2010

Recent study shows drinking coffee protects against head and neck cancer

Data on the effects of coffee on cancer risk have been mixed. However, results of a recent study add to the brewing evidence that drinking coffee protects against cancer, this time against head and neck cancer.

23 Jun 2010

TheraQuest launches new analgesic product pipeline

TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.

23 Jun 2010

Data on Qnexa to be featured in six presentations at ADA annual meeting

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be featured in a total of six presentations – including an oral presentation, three moderated poster presentations and two poster presentations – during the 70th Scientific Sessions of the American Diabetes Association, being held from June 25-29, 2010 in Orlando, Florida.

22 Jun 2010

Diabetic individuals living in hot climate need increased 'heat awareness'

A new survey shows that diabetic individuals who live in a hot climate have important gaps in their "heat awareness," or knowledge about proper diabetes self-care in hot weather, even though diabetes raises their risk of heat illness. The results of "Diabetes in the Desert: What Do Patients Know About the Heat?" will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Children with special health care needs at increased risk of oral diseases

At the beginning of 2010, as many as 17 percent of children in the United States were reported as having special health care needs. Behavioral issues, developmental disorders, cognitive disorders, genetic disorders and systemic diseases may increase a child's risk of developing oral disease, according to an article published in the May/June 2010 issue of General Dentistry, the peer-reviewed clinical journal of the Academy of General Dentistry.

22 Jun 2010

Dietary antioxidants improve insulin resistance in obese adults, study finds

A diet rich in natural antioxidants improves insulin sensitivity in insulin-resistant obese adults and enhances the effect of the insulin-sensitizing drug metformin, a preliminary study from Italy finds. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Oral micronized progesterone effective for women with symptomatic hot flashes

Postmenopausal women who experience bothersome hot flashes or night sweats may have an alternative treatment to estrogen. According to a new study, oral micronized progesterone relieves those symptoms. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Health leaders formally launch new strategy for polio eradication

Health leaders from around the world gathered on Friday to formally launch a new strategy for eradicating polio, Newsweek's "The Human Condition" blog reports in a post examining the challenges and successes health advocates face in attempting to wipe the virus out completely (Carmichael, 6/18).

22 Jun 2010

Four-year clinical study results show sustained effect that Rheos System has on reducing hypertension

CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.

22 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, was presented yesterday at the 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which is held through June 22, 2010 at the San Diego Convention Center in San Diego, California.

21 Jun 2010

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

Recently, oral cancer survivor Jeanna Richelson, organized the first Chattanooga Oral Cancer Awareness Walk, which raised donations for the Oral Cancer Foundation, and much needed awareness of a disease that too few Americans know about. According to the foundation's executive director Brian Hill, "I don't believe there has ever been an oral cancer walk that was this successful in its first year. This was an absolutely amazing effort by Jeanna and those who helped her make this possible."

21 Jun 2010

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.

21 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

Research findings support the need to establish standards for DFSA care

New toxicology findings reveal the presence of drugs and/or alcohol in 76 per cent of women and men who suspect they were victims of drug-facilitated sexual assault. Of those, 64 per cent did not report voluntarily consuming the drugs found, supporting their belief that they may have been slipped a drug. In addition, unexpected male DNA was found in a substantial number of cases, confirming sexual activity.

19 Jun 2010

Health Robotics announces new Canadian marketing contracts for i.v.STATION, i.v.SOFT

Health Robotics announced that its joint-venture Health Robotics Canada Inc. (HRCI), a leading Canadian Pharmaceutical Company, and a well-established Quebec-based Medical Device Technology company have all recently signed marketing agreements in order to expand into Canada the market presence of i.v.STATION and i.v.SOFT, revolutionary technologies that provide automated sterile compounding of intravenous medications and parenteral nutrition to hospitals.

19 Jun 2010

Oral News and Research

Healthcare policies need to adequately address dental health of entire families

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

High blood sugar in mother during pregnancy leads to reduced insulin sensitivity in children

ATP-driven bioluminescence predicts children at high risk for tooth decay: OHSU study

Recent study shows drinking coffee protects against head and neck cancer

TheraQuest launches new analgesic product pipeline

Data on Qnexa to be featured in six presentations at ADA annual meeting

Diabetic individuals living in hot climate need increased 'heat awareness'

Children with special health care needs at increased risk of oral diseases

Dietary antioxidants improve insulin resistance in obese adults, study finds

Oral micronized progesterone effective for women with symptomatic hot flashes

Health leaders formally launch new strategy for polio eradication

Four-year clinical study results show sustained effect that Rheos System has on reducing hypertension

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

Research findings support the need to establish standards for DFSA care

Health Robotics announces new Canadian marketing contracts for i.v.STATION, i.v.SOFT

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News